Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Major Program

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Completed

NCT ID

NCT01439711

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.

PURPOSE: This phase II trial is studying how well letrozole works in treating women with ductal carcinoma in situ.

Intervention

MRI, conventional surgery, letrozole

Condition

Breast Cancer

Investigators

Shelley Hwang, MD, MPH

See list of participating sites